News
-
19 February 2021
Immunocore’s tebentafusp granted Breakthrough Therapy Designation for unresectable or metastatic uveal melanoma from FDA -
16 February 2021
Immunocore announces key appointments to management and Board -
9 February 2021
Immunocore Announces Closing of $312.1 Million Aggregate Financing, Consisting of $297.1 Million Initial Public Offering, Full Exercise of Option to Purchase Additional ADSs and $15.0 Million Concurrent Private Placement -
5 February 2021
Immunocore Announces Pricing of Upsized Initial Public Offering -
11 January 2021
Immunocore announces closing of $75.0 Million Series C round -
3 December 2020
Immunocore presents Phase 2 tebentafusp clinical results at ESMO Immuno-Oncology Virtual Congress 2020 -
23 November 2020
Immunocore’s tebentafusp demonstrates superior overall survival compared to investigator’s choice in a Phase 3 clinical trial of patients with previously untreated metastatic uveal melanoma -
15 October 2020
Immunocore Appoints Nobel Laureate Professor Sir Peter J. Ratcliffe as Non-Executive Director -
27 August 2020
Immunocore announces publication of preclinical data in Hepatology showing the potential of ImmTAV® bispecific molecules for functional cure of chronic hepatitis B -
26 May 2020
Immunocore announces dosing of first patient with fourth ImmTAC